Galina Selivanova

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Galina Selivanova är professor i cell- och tumörbiologi och en av pionjärerna inom forskningen kring p53 – ett protein med central roll i skyddet mot cancer.

Artiklar

Article: BRITISH JOURNAL OF CANCER. 2022;127(11):2060-2071

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246

Zhou X; Santos GS; Zhan Y; Oliveira MMS; Rezaei S; Singh M; Peuget S; Westerberg LS; Johnsen JI; Selivanova G
Article: MOLECULAR CANCER THERAPEUTICS. 2022;21(10):1524-1534

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs

Zhan Y; Zhou X; Peuget S; Singh M; Peyser BD; Fan Z; Selivanova G
Article: ONCOGENE. 2022;41(15):2173-2186

Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization

Aschtgen M-S; Fragkoulis K; Sanz G; Normark S; Selivanova G; Henriques-Normark B; Peuget S
Article: FRONTIERS IN MOLECULAR BIOSCIENCES. 2022;9:823195

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule

Grinkevich VV; Vema A; Fawkner K; Issaeva N; Andreotti V; Dickinson ER; Hedstrom E; Spinnler C; Inga A; Larsson L-G; Karlen A; Wilhelm M; Barran PE; Okorokov AL; Selivanova G; Zawacka-Pankau JE
Article: CANCER DISCOVERY. 2021;11(12):3090-3105

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity

Zhou X; Singh M; Santos GS; Guerlavais V; Carvajal LA; Aivado M; Zhan Y; Oliveira MMS; Westerberg LS; Annis DA; Johnsen JI; Selivanova G
Journal article: CLINICAL CANCER RESEARCH. 2021;27(17):4943

Editor's Note: Dual Targeting of Wild-Type and Mutant p53 by Small-molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro.

Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Article: ISCIENCE. 2020;23(12):101785

Class IV Lasso Peptides Synergistically Induce Proliferation of Cancer Cells and Sensitize Them to Doxorubicin

Guerrero-Garzon JF; Madland E; Zehl M; Singh M; Rezaei S; Aachmann FL; Courtade G; Urban E; Rueckert C; Busche T; Kalinowski J; Cao Y-R; Jiang Y; Jiang C-L; Selivanova G; Zotchev SB
Article: BREAST CANCER RESEARCH. 2020;22(1):80

Identification and targeting of selective vulnerability rendered by tamoxifen resistance

Singh M; Zhou X; Chen X; Santos GS; Peuget S; Cheng Q; Rihani A; Arner ESJ; Hartman J; Selivanova G
Article: CANCER RESEARCH. 2020;80(7):1538-1550

Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds

Peuget S; Zhu J; Sanz G; Singh M; Gaetani M; Chen X; Shi Y; Saei AA; Visnes T; Lindstrom MS; Rihani A; Moyano-Galceran L; Carlson JW; Hjerpe E; Joneborg U; Lehti K; Hartman J; Helleday T; Zubarev R; Selivanova G
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(2):E598-598

p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture

Rangel-Pozzo A; Booth S; Yu PLI; Singh M; Selivanova G; Mai S
Article: SCIENTIFIC REPORTS. 2020;10(1):1049

Pifithrin-α alters p53 post-translational modifications pattern and differentially inhibits p53 target genes

Zhu J; Singh M; Selivanova G; Peuget S
Article: HAEMATOLOGICA. 2020;105(1):170-181

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia

Demir S; Boldrin E; Sun Q; Hampp S; Tausch E; Eckert C; Ebinger M; Handgretinger R; te Kronnie G; Wiesmueller L; Stilgenbauer S; Selivanova G; Debatin K-M; Meyer LH
Article: CELL DEATH & DISEASE. 2019;10(11):845

RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity

Ristau J; van Hoef V; Peuget S; Zhu J; Guan B-J; Liang S; Hatzoglou M; Topisirovic I; Selivanova G; Larsson O
Article: SCIENTIFIC REPORTS. 2019;9(1):2379

Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data

Franco M; Jeggari A; Peuget S; Bottger F; Selivanova G; Alexeyenko A
Article: CANCER LETTERS. 2019;442:341-350

RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism

Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
Article: CELL CYCLE. 2018;17(24):2697-2715

MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts

Zhang F; Zakaria SM; Tabor VH; Singh M; Tronnersjo S; Goodwin J; Selivanova G; Bartek J; Castell A; Larsson L-G
Journal article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2017;292(48):19607

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs (vol 280, pg 30384, 2005)

Bykov VJN; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
Journal article: KLINISCHE PADIATRIE. 2016;228(03)

Targeting mutant TP53 in ALL

Demir S; Selivanova G; Tausch E; Wiesmüller L; Stilgenbauer S; te Kronnie G; Debatin K; Meyer L
Article: CELL DEATH & DISEASE. 2015;6(1):e1616

The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death

Xu J; Eriksson SE; Cebula M; Sandalova T; Hedstrom E; Pader I; Cheng Q; Myers CR; Antholine WE; Nagy P; Hellman U; Selivanova G; Lindqvist Y; Arner ESJ
Article: FRONTIERS IN MOLECULAR BIOSCIENCES. 2015;2:39

The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors

Dickinson ER; Jurneczko E; Nicholson J; Hupp TR; Zawacka-Pankau J; Selivanova G; Barran PE
Article: CARCINOGENESIS. 2014;35(10):2273-2282

Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53

Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmueller L
Article: CELL DEATH AND DIFFERENTIATION. 2014;21(9):1493-1502

Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis

Li H; Zhang Y; Stroese A; Tedesco D; Gurova K; Selivanova G
Article: CELL DEATH AND DIFFERENTIATION. 2014;21(4):612-623

sROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis

Shi Y; Nikulenkov F; Zawacka-Pankau J; Li H; Gabdoulline R; Xu J; Eriksson S; Hedstroem E; Issaeva N; Kel A; Arner ESJ; Selivanova G
Article: CELL DEATH & DISEASE. 2013;4(10):e881

APR-246/PRIMA-1^MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng X; Zhang M-Q; Conserva F; Hosny G; Selivanova G; Bykov VJN; Arner ESJ; Wiman KG
Article: CLINICAL CANCER RESEARCH. 2013;19(18):5092-5103

Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro

Burmakin M; Shi Y; Hedstrom E; Kogner P; Selivanova G
Article: CELL DEATH AND DIFFERENTIATION. 2012;19(12):1992-2002

Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis

Nikulenkov F; Spinnler C; Li H; Tonelli C; Shi Y; Turunen M; Kivioja T; Ignatiev I; Kel A; Taipale J; Selivanova G
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2012;287(35):29336-29347

Protein Kinase Cα (PKCα) Regulates p53 Localization and Melanoma Cell Survival Downstream of Integrin αv in Three-dimensional Collagen and in Vivo

Smith SD; Enge M; Bao W; Thullberg M; Costa TDF; Olofsson H; Gashi B; Selivanova G; Stromblad S
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2011;286(48):41600-41615

Inhibition of Glycolytic Enzymes Mediated by Pharmacologically Activated p53 TARGETING WARBURG EFFECT TO FIGHT CANCER

Zawacka-Pankau J; Grinkevich VV; Huenten S; Nikulenkov F; Gluch A; Li H; Enge M; Kel A; Selivanova G
Article: CELL DEATH AND DIFFERENTIATION. 2011;18(11):1736-1745

Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX

Spinnler C; Hedstrom E; Li H; de Lange J; Nikulenkov F; Teunisse AFAS; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
Article: CELL CYCLE. 2011;10(19):3346-3358

Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2

Li H; Lakshmikanth T; Garofalo C; Enge M; Spinnler C; Anichini A; Szekely L; Karre K; Carbone E; Selivanova G
Article: CLINICAL CANCER RESEARCH. 2011;17(9):2830-2841

PRIMA-1^Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53

Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
Article: CELL CYCLE. 2011;10(2):301-307

PRIMA-1^Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo

Bao W; Chen M; Zhao X; Kumar R; Spinnler C; Thullberg M; Issaeva N; Selivanova G; Stromblad S
Article: CELL CYCLE. 2010;9(9):1847-1855

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA

Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
Article: CANCER RESEARCH. 2010;70(8):3372-3381

Rescue of p53 Function by Small-Molecule RITA in Cervical Carcinoma by Blocking E6-Mediated Degradation

Zhao CY; Szekely L; Bao W; Selivanova G
Article: CELL CYCLE. 2009;8(21):3584-3591

p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA

Hedstrom E; Eriksson S; Zawacka-Pankau J; Arner ESJ; Selivanova G
Article: CANCER RESEARCH. 2009;69(15):6241-6248

HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA

Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
Journal article: CANCER CELL. 2009;16(1):79

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

Enge M; Bao W; Hedström E; Jackson SP; Moumen A; Selivanova G
Article: CANCER CELL. 2009;15(5):441-453

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis

Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
Article: CANCER CELL. 2009;15(3):171-183

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

Enge M; Bao W; Hedstrom E; Jackson SP; Moumen A; Selivanova G
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(3):451-461

Tumor-specific induction of apoptosis by a p53-reactivating compound

Hedstrom E; Issaeva N; Enge M; Selivanova G
Journal article: APMIS. 2008;116(5):434-435

40 Identification of tumor-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy

Zandi R; Selivanova G; Poulsen HS
Journal article: APMIS. 2008;116(5):434-435

40Identification of tumor-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy

Zandi R; Selivanova G; Poulsen HS
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453

Mutated and non-mutated TP53 as targets in the treatment of leukaemia

Nahi H; Selivanova G; Lehmann S; Mollgard L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Article: EUROPEAN JOURNAL OF CANCER. 2007;43(12):1877-1882

Kaposi's sarcoma herpesvirus load in biopsies of cutaneous and oral Kaposi's sarcoma lesions

Pak F; Mwakigonja AR; Kokhaei P; Hosseinzadeh N; Pyakurel P; Kaaya E; Bogdanovic G; Selivanova G; Biberfeld P
Article: CELL DEATH AND DIFFERENTIATION. 2007;14(3):411-421

Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis

Liu T; Laurell C; Selivanova G; Lundeberg J; Nilsson P; Wiman KG
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2007;282(4):2466-2472

Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner

Zawacka-Pankau J; Issaeva N; Hossain S; Pramanik A; Selivanova G; Podhajska AJ
Article: EMBO JOURNAL. 2006;25(21):5191-5200

The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity

Okorokov AL; Sherman MB; Plisson C; Grinkevich V; Sigmundsson K; Selivanova G; Milner J; Orlova EV
Article: APOPTOSIS. 2006;11(2):221-233

HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53

Hallgren O; Gustafsson L; Irjala H; Selivanova G; Orrenius S; Svanborg C
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion

Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Journal article: BLOOD. 2005;106(11):5536

RITA Activates p53 Function in Chronic Lymphocytic Leukaemia Cells and Induces Apoptosis.

Nahi H; Merup M; Möllgård L; Selivanova G; Paul C
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(34):30384-30391

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs

Bykov VJN; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
Article: ONCOGENE. 2005;24(21):3484-3491

PRIMA-1^MET synergizes with cisplatin to induce tumor cell apoptosis

Bykov VJN; Zache N; Stridh H; Westman J; Bergman J; Selivanova G; Wiman KG
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2005;81(2):125-138

Dose-response for radiation-induced apoptosis, residual 53BP1 foci and DNA-loop relaxation in human lymphocytes

Torudd J; Protopopova M; Sarimov R; Nygren J; Eriksson S; Marková E; Chovanec M; Selivanova G; Belyaev IY
Article: JOURNAL OF CUTANEOUS PATHOLOGY. 2005;32(1):21-27

HHV-8/KSHV during the development of Kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry

Pak F; Pyakural P; Kokhaei P; Kaaya E; Pourfathollah AA; Selivanova G; Biberfeld P
Article: NATURE MEDICINE. 2004;10(12):1321-1328

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors

Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LGGC; Masucci M; Pramanik A; Selivanova G
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion

Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Journal article: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2004;2(8):62

200 Mutant p53 reactivation by PRIMA-1: a novel strategy for cancer therapy

Wiman K; Bykov V; Issaeva N; Zache N; Bergman J; Selivanova G
Article: DISCOVERY MEDICINE. 2004;4(20):28-30

Rescue of the p53 tumor suppressor by a rationally designed molecule.

Selivanova G; Fersht A
Article: CELL CYCLE. 2003;2(6):592-595

Inhibition of p53 Activity In Vitro and in Living Cells by a Synthetic Peptide Derived from Its Core Domain

Protopopova M; Selivanova G
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2003;100(23):13303-13307

Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide

Issaeva N; Friedler A; Bozko P; Wiman KG; Fersht AR; Selivanova G
Article: EUROPEAN JOURNAL OF CANCER. 2003;39(13):1828-1834

Small molecules that reactivate mutant p53

Bykov VJN; Selivanova G; Wiman KG
Article: CARCINOGENESIS. 2002;23(12):2011-2018

Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database

Bykov VJN; Issaeva N; Selivanova G; Wiman KG
Article: ONCOGENE. 2002;21(14):2119-2129

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells

Rippin TM; Bykov VJN; Freund SMV; Selivanova G; Wiman KG; Fersht AR
Article: NATURE MEDICINE. 2002;8(3):282-288

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov VJN; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2002;99(3):1532-1537

Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2-and HPV-E6-induced proteolysis

Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
Article: METHODS IN MOLECULAR BIOLOGY. 2002;203:279-288

p53 induction as an indicator of DNA damage.

Selivanova G
Article: ONCOGENE. 2001;20(39):5503-5510

Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway

Falck J; Lukas C; Protopopova M; Lukas J; Selivanova G; Bartek J
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2001;276(25):22699-22708

Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein - Functional consequences of their interaction

Grigorian M; Andresen S; Tulchinsky E; Kriajevska M; Carlberg C; Kruse C; Cohn M; Ambartsumian N; Christensen A; Selivanova G; Lukanidin E
Journal article: EUROPEAN JOURNAL OF CANCER. 2001;37:s139

p53-induced apoptosis and new cancer therapy

Wiman KG; Bykov VJ; Issaeva N; Shilov A; Bergman J; Selivanova G
Article: APOPTOSIS. 2001;6(1-2):133-137

Inactivation of Myc-induced p53-dependent apoptosis in human tumors

Henriksson M; Selivanova G; Lindström M; Wiman KG
Article: ONCOGENE. 2000;19(45):5123-5133

Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells

Xu DW; Wang Q; Gruber A; Björkholm M; Chen ZG; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P
Article: NUCLEIC ACIDS RESEARCH. 2000;28(20):4005-4012

p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core

Zotchev SB; Protopopova M; Selivanova G
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;265(1):1-6

p53-induced apoptosis as a safeguard against cancer

Asker C; Wiman KG; Selivanova G
Article: MOLECULAR AND CELLULAR BIOLOGY. 1999;19(5):3395-3402

Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain

Selivanova G; Ryabchenko L; Jansson E; Iotsova V; Wiman KG
Article: SEMINARS IN CANCER BIOLOGY. 1998;8(5):369-378

Reactivation of mutant p53: a new strategy for cancer therapy

Selivanova G; Kawasaki T; Ryabchenko L; Wiman KG
Article: NATURE MEDICINE. 1997;3(6):632-638

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

Selivanova G; Iotsova V; Okan I; Fritsche M; Strom M; Groner B; Grafstrom RC; Wiman KG
Article: NUCLEIC ACIDS RESEARCH. 1996;24(18):3560-3567

The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region

Selivanova G; Iotsova V; Kiseleva E; Strom M; Bakalkin G; Grafstrom RC; Wiman KG
Article: NUCLEIC ACIDS RESEARCH. 1995;23(3):362-369

P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH THE C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN

BAKALKIN G; SELIVANOVA G; YAKOVLEVA T; KISELEVA E; KASHUBA E; MAGNUSSON KP; SZEKELY L; KLEIN G; TERENIUS L; WIMAN KG
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1994;91(1):413-417

P53 BINDS SINGLE-STRANDED-DNA ENDS AND CATALYZES DNA RENATURATION AND STRAND TRANSFER

BAKALKIN G; YAKOVLEVA T; SELIVANOVA G; MAGNUSSON KP; SZEKELY L; KISELEVA E; KLEIN G; TERENIUS L; WIMAN KG
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1993;90(12):5455-5459

EBNA-5, AN EPSTEIN-BARR VIRUS-ENCODED NUCLEAR ANTIGEN, BINDS TO THE RETINOBLASTOMA AND P53 PROTEINS

SZEKELY L; SELIVANOVA G; MAGNUSSON KP; KLEIN G; WIMAN KG
Journal article: RUSSIAN JOURNAL OF GENETICS. 1992;28(5):66-72

ISOLATION AND ANALYSIS OF PROTEASE DEFICIENT MUTANTS OF BACILLUS-AMYLOLIQUEFACIENS

PLOTNIKOVA TG; SELIVANOVA GN; JOMANTAS JV; KOZLOV YI
Visa fler

Alla övriga publikationer

Review: NATURE REVIEWS CANCER. 2024;24(3):192-215

Translating p53-based therapies for cancer into the clinic

Peuget S; Zhou X; Selivanova G
Editorial comment: CANCER DISCOVERY. 2023;13(5):1043-1045

MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation

Peuget S; Selivanova G
Conference publication: CANCER SCIENCE. 2023;114:249

Pharmacological activation of p53 triggers viral mimicry response thereby promoting anti-tumor immunity

Selivanova G; Zhou X; Singh M; Sanz G; Guerlavais V; Carvajal LA; Aivado M; Annis A; Zhan Y; Oliveira M; Westerberg L; Johnsen JI
Preprint: BIORXIV. 2021

Novel allosteric mechanism of dual p53/MDM2 and p53/MDM4 inhibition by a small molecule

Grinkevich VV; Aparna V; Fawkner K; Issaeva N; Andreotti V; Dickinson ER; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Wilhelm M; Barran PE; Okorokov AL; Selivanova G; Zawacka-Pankau JE
Editorial comment: CANCERS. 2021;13(19):4850

p53-Dependent Repression: DREAM or Reality?

Peuget S; Selivanova G
Review: JOURNAL OF MOLECULAR CELL BIOLOGY. 2019;11(7):586-599

Inhibition of p53 inhibitors: progress, challenges and perspectives

Sanz G; Singh M; Peuget S; Selivanova G
Preprint: BIORXIV. 2018

Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy

Zawacka-Pankau J; Grinkevich V; Burmakin M; Vema A; Fawkner K; Issaeva N; Andreotti V; Dickinson E; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Tarasova O; Poroikov V; Lavrenov S; Preobrazhenskaya M; Barran P; Okorokov A; Selivanova G
Preprint: BIORXIV. 2018

Robust and clinically relevant prediction of response to anti-cancer drugs via network integration of molecular profiles

Franco M; Jeggari A; Peuget S; Böttger F; Selivanova G; Alexeyenko A
Preprint: SSRN ELECTRONIC JOURNAL. 2018

Novel Allosteric Mechanism of P53 Activation by Small Molecules for Targeted Anticancer Therapy

Zawacka-Pankau J; Grinkevich VV; Burmakin M; Vema A; Ridderstråle K; Issaeva N; Andreotti V; Dickinson ER; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Tarasova O; Poroikov V; Lavrenov S; Preobrazhenskaya M; Wilhelm M; Barran PE; Okorokov AL; Selivanova G
Corrigendum: CANCER CELL. 2017;31(5):724-726

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis (vol 15, pg 441, 2009)

Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
Corrigendum: CELL DEATH & DISEASE. 2017;8(4):e2751

APR-246/PRIMA-1^MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase (vol 4, e881, 2013)

Peng X; Zhang M-Q; Conserva F; Hosny G; Selivanova G; Bykov VJN; Arner ESJ; Wiman KG
Conference publication: PEDIATRIC BLOOD & CANCER. 2017;64:S70

Therapeutic Targeting of Mutant P53 in Pediatric Acute Lymphobastic Leukemia

Demir S; Sun Q; Tausch E; Stilgenbauer S; te Kronnie G; Eckert C; Wiesmueller L; Selivanova G; Debatin KM; Meyer L
Conference publication: ANNALS OF HEMATOLOGY. 2017;96:S73

Targeting Mutant p53 in Acute Lymphoblastic Leukemia as a Novel Therapeutic Strategy

Demir S; Sun Q; Tausch E; Stilgenbauer S; Kronnie GT; Wiesmueller L; Selivanova G; Debatin K-M; Meyer LH
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2016;39:200

Mutant p53 as a novel therapeutic target in Acute Lymphoblastic Leukemia

Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin K-M; Meyer LH
Conference publication: HAEMATOLOGICA. 2016;101:28

FUNCTIONAL RESTORATION OF MUTANT P53 AND CELL DEATH SENSITIZATION IN ACUTE LYMPHOBLASTIC LEUKEMIA

Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin KM; Meyer LH
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2016;39:117

APR-246 targets pediatric acute lymphoblastic leukemia carrying mutant P53

Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin K-M; Meyer L
Conference publication: BLOOD. 2015;126(23):903

Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia

Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; Te Kronnie G; Debatin K-M; Meyer LH
Conference publication: CANCER RESEARCH. 2015;75:503

The PPM1D encoded phosphatase Wip1 is a novel oncogene and potential therapeutic target in neuroblastoma and medulloblastoma

Miloseyic J; Treis D; Wickstrom M; Fransson S; Eissler N; Syeinbjornsson B; Baryawno N; Tanino K; Selivanova G; Sakaguchi K; Martinsson T; Johnsen JI; Kogner P
Review: JOURNAL OF INTERNAL MEDICINE. 2015;277(2):248-259

Pharmacological reactivation of p53 as a strategy to treat cancer

Zawacka-Pankau J; Selivanova G
Conference publication: PEDIATRIC BLOOD & CANCER. 2015;62:S332

THE PPM1D ENCODED PHOSPHATASE WIP1 IS A NOVEL ONCOGENE AND POTENTIAL THERAPEUTIC TARGET IN NEUROBLASTOMA AND MEDULLOBLASTOMA

Milosevic J; Treis D; Malin M; Fransson S; Sveinbjornsson B; Eissler N; Baryawno N; Tanino K; Selivanova G; Sakaguchi K; Martinsson T; Johnsen JI; Kogner P
Review: FEBS LETTERS. 2014;588(16):2628-2638

Wild type p53 reactivation: From lab bench to clinic

Selivanova G
Book chapter: P53 IN THE CLINICS. 2013;p. 231-255

p53-Reactivating Molecules as Research Tools and Anticancer Drugs

Grinkevich VV; Warnecke A; Selivanova G
Editorial comment: ONCOIMMUNOLOGY. 2012;1(4):541-543

A novel facet of tumor suppression by p53 Induction of tumor immunogenicity

Li H; Lakshmikanth T; Carbone E; Selivanova G
Review: SEMINARS IN CANCER BIOLOGY. 2010;20(1):46-56

Therapeutic targeting of p53 by small molecules

Selivanova G
Editorial comment: CELL. 2009;139(7):1220-1222

Integrins and Mutant p53 on the Road to Metastasis

Selivanova G; Ivaska J
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2009;4(9):S592-S593

Identification of tumour-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy

Zandi R; Selivanova G; Willumsen BM; Poulsen HS
Conference publication: CANCER RESEARCH. 2009;69

Identification of tumor-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule can be used for cancer gene therapy.

Zandi R; Selivanova G; Willumsen B; Poulsen H
Review: TOXICOLOGY AND APPLIED PHARMACOLOGY. 2008;232(3):487-497

The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances

Zawacka-Pankau J; Krachulec J; Grulkowski I; Bielawski KP; Selivanova G
Conference publication: APMIS. 2008;116(5):434-435

Identification of tumor-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy

Zandi R; Selivanova G; Poulsen HS
Review: ONCOGENE. 2007;26(15):2243-2254

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

Selivanova G; Wiman KG
Book chapter: 25 YEARS OF P53 RESEARCH. 2007;p. 399-419

Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy

Selivanova G; Bykov VJN; Wiman KG
Book chapter: APOPTOSIS AND CANCER THERAPY. 2006;p. 891-912

Cancer Therapy by Reactivation of the p53 Apoptosis Pathway

Stridh H; Bykov VJN; Selivanova G; Wiman KG
Conference publication: ACTA PHARMACOLOGICA SINICA. 2006;27:412-413

Identifying and charactering novel p53 regulated genes for potential anticancer therapy

Liu T; Laurell C; Selivanova G; Lundeberg J; Nilson P; Wiman KG
Letter: NATURE MEDICINE. 2005;11(11):1136-1137

NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro -: Reply

Grinkevich V; Issaeva N; Hossain S; Pramanik A; Selivanova G
Published conference paper: BIOELECTROMAGNETICS. 2005;26(3):173-184

915 MHz microwaves and 50 Hz magnetic field affect chromatin conformation and 53BP1 foci in human lymphocytes from hypersensitive and healthy persons

Belyaev IY; Hillert L; Protopopova M; Tamm C; Malmgren LOG; Persson BRR; Selivanova G; Harms-Ringdahl M
Conference publication: ANNALS OF ONCOLOGY. 2005;16:23-24

Mutant p53 reactivation as a novel strategy for cancer therapy

Wiman KG; Stridh H; Zache N; Rökaeus N; Issaeva N; Hammarsund M; Shen JF; Bergman J; Westman J; Selivanova G; Bykov VJN
Conference publication: BLOOD. 2005;106(11):472B

RITA activates p53 function in chronic lymphocytic leukaemia cells and induces apoptosis.

Nahi H; Merup M; Möllgård L; Selivanova G; Paul C
Review: CURRENT CANCER DRUG TARGETS. 2004;4(5):385-402

p53: Fighting cancer

Selivanova G
Book chapter: TRANSCRIPTION FACTORS: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2004;p. 209-258

The p53 Transcription Factor as Therapeutic Target in Cancer

Asker C; Bykov VJN; Mendez-Vidal C; Selivanova G; Wilhelm MT; Wiman KG
Conference publication: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2002;11(10):1227S-1228S

Distinct p53 domains recognize different type of lesions

Protopopova M; Selivanova G
Book chapter: TUMOR SUPPRESSING VIRUSES, GENES, AND DRUGS. 2002;p. 397-415

Functional Rescue of Mutant p53 as a Strategy to Combat Cancer

Selivanova G; Wiman KG
Review: CURRENT OPINION IN INVESTIGATIONAL DRUGS. 2001;2(8):1136-1141

Mutant p53: the loaded gun.

Selivanova G
Conference publication: CLINICAL CANCER RESEARCH. 2001;7(11):3749S

Restoration of the tumor suppressor function of mutant p53 by a low molecular weight compound.

Bykov VJ; Issaeva N; Shilov A; Bergman J; Selivanova G; Wiman KG
Conference publication: CLINICAL CANCER RESEARCH. 2001;7(11):3792S

Restoration of transcriptional transactivation function of mutant p53 by small molecules.

Issaeva N; Shilov A; Bykov V; Wiman K; Selivanova G
Other: ONCOGENE. 1995;10(9):1869-1874

RESTING B-CELLS, EBV-INFECTED B-BLASTS AND ESTABLISHED LYMPHOBLASTOID CELL-LINES DIFFER IN THEIR RB, P53 AND EBNA-5 EXPRESSION PATTERNS

SZEKELY L; POKROVSKAJA K; JIANG WQ; SELIVANOVA G; LOWBEER M; RINGERTZ N; WIMAN KG; KLEIN G
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1995;:325

P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN

SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; KISELEVA E; SZEKELY L; TERENIUS L; WIMAN KG
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 1995;66:143-180

P53 - A CELL-CYCLE REGULATOR ACTIVATED BY DNA-DAMAGE

SELIVANOVA G; WIMAN KG
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1995;:77

P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN

SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; KISELEVA E; SZEKELY L; TERENIUS L; WIMAN KG
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1994;:181

P53 BINDS SINGLE-STRANDED-DNA ENDS AND CATALYZES DNA RENATURATION AND STRAND TRANSFER

SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; MAGNUSSON KP; SZEKELY L; KISELEVA E; KLEIN G; TERENIUS L; WIMAN KG
Visa fler

Forskningsbidrag

Targeting p53 to kill tumor cells, reprogram cancer-associated fibroblasts and boost anti-cancer immune response

Swedish Research Council

1 January 2020 - 31 December 2023
To tame p53 and have a long cancer-free life, continued

Swedish Cancer Society

1 January 2018
To tame p53 to live longer without cancer

Swedish Cancer Society

1 January 2017
Targeting p53 pathway to combat cancer: from lab bench to patient

Swedish Research Council

1 January 2016 - 31 December 2019
To tame p53 to live longer without cancer

Swedish Cancer Society

1 January 2016
To tame p53 to live longer without cancer

Swedish Cancer Society

1 January 2015
To target p53 networks to fight cancer: from the lab bank to the hospital

Swedish Cancer Society

1 January 2014
Novel treatment of advanced melanoma by targeted pro-senescence therapy combined with immunotherapy

Knut and Alice Wallenberg Foundation

1 January 2013 - 1 January 2018
Rational design of synergistic combinations of target-specific anti-cancer drugs

Ragnar Söderberg Foundation

1 January 2012 - 31 December 2014
Targeting p53 pathway: from lab bench to patient

Swedish Research Council

1 January 2011 - 31 December 2015

Anställningar

Professor, Institutionen för mikrobiologi, tumör- och cellbiologi, Karolinska Institutet, 2010-

Examina och utbildning

Docent, Genetik, Karolinska Institutet, 2002

Om mig

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI